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Abstract
Background: Candidemia is a common cause of nosocomial bloodstream infections, resulting in high morbidity
and mortality. This study was conducted to describe the epidemiology, species distribution, antifungal susceptibility
patterns and outcomes of candidemia in a large regional tertiary referral hospital.
Methods: A retrospective surveillance study of patients with candidemia was conducted at Singapore General
Hospital between July 2012 and December 2015. In addition, incidence densities and species distribution of
candidemia episodes were analysed from 2008 to 2015.
Results: In the period of 2012 to 2015, 261 candidemia episodes were identified. The overall incidence was 0.14/1000
inpatient-days. C. glabrata (31.4%), C. tropicalis (29.9%), and C. albicans (23.8%) were most commonly isolated.
The incidence of C. glabrata significantly increased from 2008 to 2015 (Coefficient 0.004, confidence interval
0–0.007, p = 0.04). Fluconazole resistance was detected primarily in C. tropicalis (16.7%) and C. glabrata (7.2%).
fks mutations were identified in one C. albicans and one C. tropicalis. Candidemia episodes caused by C.
tropicalis were more commonly encountered in patients with haematological malignancies (p = 0.01),
neutropenia (p < 0.001) and higher SAPS II scores (p = 0.02), while prior exposure to echinocandins was
associated with isolation of C. parapsilosis (p = 0.001). Echinocandins (73.3%) were most commonly prescribed
as initial treatment. The median (range) time to initial treatment was 1 (0–9) days. The 30-day in-hospital
mortality rate was 49.8%. High SAPS II score (Odds ratio, OR 1.08; 95% confidence interval, CI 1.05–1.11) and
renal replacement therapy (OR 5.54; CI 2.80–10.97) were independent predictors of mortality, while drain
placement (OR 0.44; CI 0.19–0.99) was protective.
Conclusions: Decreasing azole susceptibilities to C. tropicalis and the emergence of echinocandin resistance
suggest that susceptibility patterns may no longer be sufficiently predicted by speciation in our institution.
Candidemia is associated with poor outcomes. Strategies optimising antifungal therapy, especially in the
critically-ill population, should be explored.
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Background
Candida species are the leading cause of invasive fungal
infections and a common cause of hospital-acquired
bloodstream infections [1]. Candidemia has a profound
impact on patient outcomes and the burden has in-
creased significantly over the years. The crude mortality
is high, ranging from 30–50% [2–4]; while the attribut-
able mortality due to candidemia varied from 15–49%
[5, 6]. Increasing reports of antifungal resistance, even in
newer agents such as the echinocandins, further escalate
the complexity in the management of candidemia [7].
Knowledge of antifungal susceptibility patterns is im-
perative in the selection of early and appropriate anti-
fungal agents for improved patient outcomes. The
variable epidemiology of candidemia, contributed by the
geographical and temporal variations in incidence and
species distribution [4, 8–10], underscores the continu-
ing need for local surveillance of Candida species distri-
bution and susceptibility patterns.
Furthermore, the introduction of new echinocandins
into Singapore such as anidulafungin in 2008 and mica-
fungin in 2013, coupled with the exponential increase in
echinocandin usage in our institution for the past 5 years,
suggest that current susceptibility patterns should be
reviewed. A recent study has also reported the emer-
gence of echinocandin resistance in the Asia-Pacific
region [11]. The objectives of this study were 1) to inves-
tigate the incidence, species distribution and antifungal
susceptibilities of candidemia, and 2) to describe the
clinical features and outcomes of candidemia in our
population.
Methods
Study setting and design
A retrospective surveillance study of patients with candi-
demia was conducted at Singapore General Hospital
(SGH) between July 2012 and December 2015. SGH is
the largest acute care hospital (1800 beds) in the coun-
try, and covers a wide range of medical and surgical
specialties. The hospital is the national/regional referral
centre for services such as plastic surgery and burns,
renal medicine, nuclear medicine, pathology and haema-
tology. SGH accounts for approximately 25% of the total
acute hospital beds in the public sector and 20% of acute
beds nationwide.
All adult inpatients (at least 21 years old) with ≥ 1
positive blood culture for Candida spp. were included
into the study. Each positive Candida culture must be
accompanied with temporally-related clinical signs and
symptoms of infection for inclusion into the study. For
each patient, only the first candidemia episode was re-
corded, unless the positive blood culture was obtained ≥
30 days (with blood culture clearance and resolution of
clinical features of infection of the first episode) or
involved a different Candida spp. isolated from blood
culture obtained ≥ 7 days after the first episode. Episodes
involving > 1 Candida spp. isolated within 7 days of the
first episode, defined as “mixed candidemia”, were
regarded as a single episode.
Microbiology and antifungal susceptibility testing
Candida spp. were isolated from blood using BD BAC-
TEC™ FX (Becton, Dickinson and Company, Sparks,
MD). The species were identified using MALDI Biotyper
(BrukerDaltonik GmbH, Germany), morphology studies
on cornmeal Tween 80 agar, and API 20C AUX
(Biomerieux, Marcy l’Etoile, France). Isolates were stored
in MicrobankTM storage vials (Pro-Lab Diagnostics,
Round Rock, TX, USA) at −70 °C until testing.
Antifungal susceptibility testing was performed using
Sensititre YeastOne® YO10 panel (Trek Diagnostics Sys-
tem, West Sussex, England) according to manufacturer’s
recommendations. Minimum inhibitory concentrations
(MICs) for amphotericin B, anidulafungin, caspofungin,
micafungin, fluconazole, voriconazole, itraconazole,
posaconazole and flucytosine were recorded. Candida
krusei (Issatchenkia orientalis) ATCC 6258 and C. para-
psilosis ATCC 22019 (American Type Culture Collec-
tion, Manassas, Virginia) were used as quality controls.
MICs were interpreted according to the current
species-specific clinical breakpoints provided by the
Clinical and Laboratory Standards Institute (CLSI) M27-
S4 document [12]. Where clinical breakpoints were not
available, the epidemiological cut-off values (ECV) were
used to classify the isolates into wild-type or non-wild-
type populations [13–15].
Detection of fks mutations
Isolates classified as intermediate or resistant to echino-
candins were tested for the presence of mutations in the
fks genes. Hot spots 1 and 2 regions of fks1 and fks2 (for
C. glabrata only) genes were amplified using polymerase
chain reaction (PCR), as described previously [16].
Clinical data collection
Clinical characteristics of patients with candidemia were
obtained from inpatient charts and electronic medical
records using a standardised case report form. Data ex-
tracted included demographics, hospitalisation history
(previous hospital stay, previous intensive care unit
(ICU) stay, length of hospital stay prior to candidemia),
underlying medical conditions and prior exposure to in-
vasive interventions (central lines, urinary catheters,
drainage devices, invasive ventilation, dialysis, invasive
surgery, total parenteral nutrition) and medical therapy
(chemotherapy, immunosuppressive therapy, antibiotics,
antifungal agents) within 30 days before the first positive
blood culture. Charlson comorbidity index at the time of
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admission and Simplified Acute Physiology Score (SAPS)
on the day of the first positive blood culture were also
recorded. Information on the management of candide-
mia (choice and duration of antifungal agents) and
outcome (in-hospital all-cause mortality within 30 days)
were collected.
Data and statistical analyses
To calculate and analyse the incidence of candidemia, the
number of candidemia episodes were obtained from the
clinical microbiology laboratory computerised database,
while inpatient-days were obtained from the hospital ad-
ministrative database. Incidence data was available from
2008, hence trend analyses were performed for the period
from 2008 to 2015. Incidence rates were calculated as the
number of candidemia episodes per 1000 inpatient-days.
Linear regression was used to determine trends over time
in the incidences of candidemia.
Categorical variables were presented as numbers and
percentages; and were compared using the Χ2 or Fisher’s
exact test, as appropriate. Continuous variables were
presented as mean ± SD or median and range; and were
compared using the Student’s t test, Mann–Whitney
test, or Kruskal-wallis test, depending on the validity of
the normality assumption.
A multivariable logistic regression model was used to
identify predictors associated with 30-day mortality.
Clinically plausible variables identified in the bivariate
analysis were included in the multivariable logistic re-
gression model if p < 0.1. Significant factors which may
covary were grouped and only one factor from each
group was selected for entry into the model. The final
model was chosen on the basis of biologic plausibility.
Odds ratios (OR) and 95% confidence intervals (CI) were
calculated to evaluate the strength of any association.
For all calculations, a 2-tailed p value of less than 0.05
was considered to reveal a statistical significant differ-
ence. Statistical analyses were performed using IBM
SPSS Statistics for Windows, Version 23.0 (IBM Corp.,
Armonk, NY).
Results
Incidence and species distribution
From 2012 to 2015, 261 candidemia episodes involving
254 patients and 272 isolates were analysed. Seven
patients had two separate episodes each with distinct
Candida species, while a patient had a repeated episode
involving the same Candida species. The incidence was
0.14 episodes per 1000 inpatient-days during the study
period. C. glabrata (82/261, 31.4%), C. tropicalis (78/261,
29.9%), C. albicans (62/261, 23.8%), and C. parapsilosis
(36/261, 13.8%) accounted for majority of the episodes.
Other species including C. dubliniensis (n = 7), C. krusei
(n = 3), C. guilliermondii (Meyerozyma guilliermondii)
(n = 1), C. kefyr (Kluyveromyces marxianus) (n = 1), C.
haemulonis (n = 1) and C. pseudohaemulonii (n = 1)
accounted for the remaining episodes. Of these 261 epi-
sodes, 11 (4.2%) were mixed candidemia episodes.
The incidence density and species distribution are
displayed in Fig. 1. The overall incidence density was
0.15 (range 0.12–0.18) episodes/1000 inpatient-days
and 0.89 (range 0.74–1.05) episodes/1000 admissions
from 2008 to 2015. Analysing the incidence densities
from 2008 to 2015, we found no significant change in
the incidence density of candidemia [Coefficient
0.00009, confidence interval (CI) - 0.007–0.007, p = 0.98].
Fig 1 Incidence densities of candidemia episodes and distribution of Candida species from 2008 to 2015
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However, we did note that the overall incidence density
increased from 0.14 in 2014 to 0.18 episodes/1000
inpatient-days in 2015, suggesting the need for continual
monitoring. There was a significant increasing trend in
the incidence density of C. glabrata (Coefficient 0.004, CI
0–0.007, p = 0.04), while the incidence densities of the
other Candida spp. remained stable. The proportions of
C. glabrata increased from 11.3% in 2008 to 31.6% in
2015 and that of C. albicans decreased from 44% in 2008
to 19% in 2015.
Antifungal susceptibilities
Antifungal susceptibilities were available for 271 isolates,
except for one C. parapsilosis (Table 1). Among isolates
with available clinical breakpoints, overall susceptibility
rates were 59.5% (153/257) for fluconazole, 86.9% (152/
175) for voriconazole, 99.2% (255/257) for anidulafungin,
98.1% (252/257) for caspofungin and 98.9% (254/257)
for micafungin. Using the clinical breakpoints, C. albi-
cans and C. parapsilosis retained high susceptibility
(>94%) to fluconazole and voriconazole. However, more
than 20% of the C. tropicalis isolates were non-
susceptible to fluconazole and voriconazole. The propor-
tions of isolates classified as wild-type (MIC value less
than or equals to ECV) for fluconazole, voriconazole,
itraconazole and posaconazole were similar among C.
albicans, C. glabrata and C. parapsilosis (ranged from
94–100%). Decreased susceptibilities (non wild-type;
MIC value greater than ECV) to fluconazole and vorico-
nazole were prominent in C. tropicalis isolates. Echino-
candin resistance was rare, occurring only in three
isolates (C. albicans = 1; C. tropicalis =1 and C. glabrata
= 1) when assessed using both clinical breakpoints and
ECVs. Most isolates had amphotericin B and flucytosine
MICs below ECVs (96–100%), although a number of C.
parapsilosis were classified as non-wild-type (20%). The
amphotericin B MICs of these non-wild-type isolates
were 2 μg/mL, which were just one dilution above the
ECV (1 μg/mL) utilised in this study. Furthermore, the
ECV used in this study was derived using the YeastOne®
method and is one dilution lower than the ECVs for the
other species (2 μg/mL) and the ECV derived from broth
dilution methods.
fks mutations were detected in the echinocandin-
resistant C. albicans (caspofungin MIC 4 μg/mL; anidu-
lafungin MIC 0.25 μg/mL; micafungin MIC 2 μg/mL)
and C. tropicalis (caspofungin MIC 2 μg/mL; anidula-
fungin MIC 0.5 μg/mL; micafungin 1 μg/mL) isolates.
Both isolates harboured a point mutation (S645P in C.
albicans and S80P in C. tropicalis) in the hotspot 1
region of the fks1 gene. The two isolates remained sus-
ceptible to all other antifungals. Interestingly, fks muta-
tions were not identified in the C. glabrata isolate which
was resistant (caspofungin MIC ≥ 8 μg/mL; anidulafun-
gin MIC 4 μg/mL; micafungin MIC 4 μg/mL).
Clinical characteristics
The clinical characteristics of the candidemia episodes
are summarised in Table 2. The median age of patients
with candidemia was 65 years and incidence did not dif-
fer by gender (52.9% male vs. 47.1% female, p = 0.59).
The episodes occurred primarily in the medical wards
(42.1%), followed by intensive care units (ICUs) (38.3%),
surgical wards (19.5%). Patients admitted to haematology-
oncology (19.9%), internal medicine (19.5%) and general
surgery units (12.3%) encountered the most episodes.
Most of the patients presented with multiple comor-
bidities (median Charlson score = 5, range 0–15), with
many having malignancies (40.6%). Diabetes was also
common among these patients (39.5%). Prior antibiotic
exposure (90.4%), central venous catheter placement
(73.6%), and surgery (65.1%) were common risk factors.
A large number of patients were colonised or infected
with Candida at other non-blood sites (45.2%) and had
concurrent bacterial infections (48.7%). In addition, it
appears that candidemia episodes caused by C. tropicalis
were more commonly encountered in patients with
haematological malignancies (p = 0.01), neutropenia
(p < 0.001) and higher SAPS II scores (p = 0.02). Ex-
posure to echinocandins was also associated with
candidemia episodes caused by C. parapsilosis (p = 0.001).
Antifungal therapy and outcomes
Antifungal therapy was initiated in 225 (86.2%) episodes
(Table 2). All but six of the 36 patients who did not re-
ceive treatment died before blood cultures flagged posi-
tive. Treatment was not initiated in four patients as they
were conservatively managed. Interestingly, physicians
elected not to initiate treatment in the remaining two
patients.
Echinocandins were the initial treatment of choice
(73.3%), followed by azoles (23.1%). Caspofungin (93.4%)
was more commonly used, since it was the only echino-
candin in the formulary until anidulafungin’s inclusion
in August 2015. Among the patients receiving treatment,
32 (14.2%) were already receiving antifungals as prophy-
laxis or empiric treatment on the day which cultures
were taken. Fluconazole was the only azole used as ini-
tial treatment of candidemia in our institution. The me-
dian (range) time to initial treatment was 1 (0–9) days.
Treatment was initiated in 73 (32.4%) patients on day of
culture and in 172 (76.4%) patients within two days. The
median (range) duration of therapy was 15 (1–140) days.
Patients with candidemia were moderately to severely-
ill – 57.9% were having severe sepsis and the median
(range) SAPS II score was 49 (14–103) at the time of
culture. Many of these episodes (38.3%) occurred in
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%Sb %SDD/Ib %Rb %WTc
C albicans (n = 62)
Fluconazole 0.5 2 ≤0.12–>256 95.2 1.6 3.2 93.5
Itraconazole 0.06 0.12 ≤0.015–>16 – – – 96.7
Posaconazole 0.015 0.06 ≤0.08–>8 – – – 96.7
Voriconazole ≤0.008 0.03 ≤0.008–>8 93.6 3.2 3.2 93.5
Anidulafungin ≤0.015 0.03 ≤0.015–0.25 100 0 0 98.4
Caspofungin 0.03 0.06 0.015–4 98.4 0 1.6 98.4
Micafungin ≤0.008 0.015 ≤0.008–2 98.4 0 1.6 98.4
Flucytosine ≤0.06 0.25 ≤0.06–>64 – – – 96.7
Amphotericin B 0.5 1 ≤0.12–1 – – – 100
C. glabrata (n = 82)
Fluconazole 16 32 1–>256 – 92.8 7.2 97.6
Itraconazole 1 1 0.12–>16 – – – 93.9
Posaconazole 2 2 0.12–>8 – – – 95.1
Voriconazole 0.5 2 0.03–>8 – – – 97.6
Anidulafungin 0.03 0.06 ≤0.015–4 98.8 0 1.2 98.7
Caspofungin 0.12 0.12 0.03–>8 96.4 2.4 1.2 96.3
Micafungin 0.015 0.015 ≤0.008–4 98.8 0 1.2 98.7
Flucytosine ≤0.06 0.12 ≤0.06–0.25 – – – 100
Amphotericin B 1 1 0.25–2 – – – 100
C. tropicalis (n = 78)
Fluconazole 2 64 0.5–>256 78.2 5.1 16.7 84.6
Itraconazole 0.25 0.5 0.03–>16 – – – 96.1
Posaconazole 0.12 0.5 0.03–4 – – – 98.7
Voriconazole 0.12 4 ≤0.008–>8 75.6 11.5 12.8 80.8
Anidulafungin 0.03 0.12 ≤0.015–0.5 98.7 1.3 0 98.7
Caspofungin 0.03 0.06 0.015–2 98.7 0 1.3 98.7
Micafungin 0.03 0.03 ≤0.008–1 98.7 0 1.3 98.7
Flucytosine ≤0.06 0.12 ≤0.06–32 – – – 96.2
Amphotericin B 1 1 0.25–2 – – – 100
C. parapsilosis (n = 35)
Fluconazole 0.5 2 0.25–4 97.1 2.9 0 100
Itraconazole 0.06 0.06 ≤0.015–0.12 – – – 100
Posaconazole 0.03 0.06 0.015–0.12 – – – 100
Voriconazole 0.015 0.03 ≤0.008–0.6 100 0 0 97.1
Anidulafungin 0.5 2 0.12–2 100 0 0 100
Caspofungin 0.25 0.5 0.06–1 100 0 0 100
Micafungin 0.5 2 0.12–2 100 0 0 100
Flucytosine ≤0.06 0.5 ≤0.06–1 – – – 100
Amphotericin B 1 2 0.25–2 – – – 80.0
S susceptible, SDD susceptible dose-dependent, I intermediate, R resistant, WT wild-type
aMICs are only reflected for the predominant species
bSusceptibilities were assessed based on CLSI species-specific clinical interpretative breakpoints [12]. Clinical breakpoints are not available for itraconazole,
posaconazole, flucytosine and amphotericin B for all species and voriconazole for C. glabrata
cECVs were derived from [13, 14] and [15]
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Table 2 Clinical characteristics of candidemia episodes
All C. glabrata C. tropicalis C. albicans C. parapsilosis p
n = 261 n = 75 (28.6%) n = 71 (27.1%) n = 59 (22.6%) n = 33 (12.6%)
Demographics
Male sex 138 (52.9) 37 (49.3) 39 (54.9) 32 (54.2) 22 (66.7) 0.42
Median age (range) 65 (22–101) 67 (24–95) 63 (28–90) 68 (27–101) 61 (28–86) 0.06
Ward type 0.83
Medical ward 110 (42.1) 30 (40.0) 35 (49.3) 23 (39.0) 14 (42.4)
Surgical ward 51 (19.5) 16 (21.3) 10 (14.1) 14 (23.7) 7 (21.2)
ICU 100 (38.3) 29 (38.7) 26 (36.6) 22 (37.3) 12 (36.4)
Elective admission 27 (10.3) 12 (16.0) 5 (7.0) 5 (8.5) 4 (12.1) 0.32
Comorbidities
Malignancies 106 (40.6) 34 (45.3) 29 (40.8) 23 (39.0) 12 (36.4) 0.81
Haematological 27 (10.3) 3 (4.0) 13 (18.3) 6 (10.2) 2 (6.1) 0.03
Oncological 84 (32.2) 32 (42.7) 17 (23.9) 18 (30.5) 11 (33.3) 0.11
With metastases 36 (13.8) 16 (21.3) 11 (15.5) 6 (10.2) 3 (9.1) 0.23
Diabetes 103 (39.5) 31 (41.3) 25 (35.2) 23 (39.0) 12 (36.4) 0.89
Chronic renal failure 67 (25.7) 17 (22.7) 22 (31.0) 14 (23.7) 8 (24.2) 0.67
Hepatobiliary disorders 58 (22.2) 17 (22.7) 20 (28.2) 8 (13.6) 8 (24.2) 0.25
Myocardial infarction 43 (16.5) 10 (13.3) 13 (18.3) 15 (25.4) 1 (3.0) 0.04
Cerebrovascular disease 29 (11.1) 12 (16.0) 8 (11.3) 4 (6.8) 4 (12.1) 0.44
Median (range) Charlson score 5 (0–15) 6 (0–15) 5 (0–14) 4 (0–12) 4 (0–9) 0.08
Risk factors
Central venous catheter 192 (73.6) 47 (62.7) 55 (77.5) 46 (78.0) 26 (78.8) 0.11
Drain 60 (23.0) 22 (29.3) 14 (19.7) 16 (27.1) 6 (18.2) 0.43
Mechanical ventilation 111 (42.5) 26 (34.7) 31 (43.7) 25 (42.4) 16 (48.5) 0.52
Total parenteral nutrition 52 (19.9) 12 (16.0) 13 (18.3) 12 (20.3) 10 (30.3) 0.37
Surgery 170 (65.1) 51 (68.0) 44 (66.0) 39 (66.1) 20 (60.6) 0.83
Gastrointestinal surgery 41 (15.7) 18 (24.0) 5 (7.0) 9 (24.3) 5 (15.2) 0.05
Renal replacement therapy 85 (32.6) 16 (21.3) 28 (39.4) 21 (35.6) 12 (36.4) 0.10
Antimicrobial therapy 236 (90.4) 67 (89.3) 68 (95.8) 53 (89.8) 27 (81.8) 0.15
Antifungal therapy 51 (19.5) 13 (17.3) 15 (21.1) 8 (13.6) 11 (33.3) 0.13
Azole 24 (9.2) 5 (6.7) 10 (14.1) 6 (10.2) 2 (6.1) 0.41
Echinocandin 30 (11.5) 8 (10.7) 6 (8.5) 2 (3.4) 10 (30.3) 0.001
Immunosuppressive therapy 76 (29.1) 17 (22.7) 28 (39.4) 16 (27.1) 10 (30.3) 0.16
Neutropenia 21 (8.0) 3 (4.0) 13 (18.3) 2 (3.4) 2 (6.1) 0.004
Therapy
Primary therapy 0.15
Echinocandin 165 (73.3) 45 (76.3) 49 (81.7) 32 (60.4) 22 (71.0)
Azole 52 (23.1) 12 (20.3) 11 (18.3) 17 (32.0) 8 (25.8)
Others 8 (3.1) 2 (3.3) 1 (1.7) 4 (6.8) 1 (3.2)
None 36 (13.8) 16 (21.3) 10 (14.1) 6 (10.2) 2 (6.1)
Median (range) time to primary
therapy, days
1 (0–9) 2 (0–7) 1 (0–3) 2 (0–5) 1 (0–9) 0.01
Median (range) duration of
therapy, days
15 (1–140) 16 (2–61) 11 (1–96) 16 (1–140) 15 (2–47) 0.01
Teo et al. Antimicrobial Resistance and Infection Control  (2017) 6:27 Page 6 of 11
critically-ill patients warded in the ICUs. We also ob-
served that some patients (11.9%), who were initially in
the general wards at the time of culture, required admis-
sion into the ICU after Candida isolation, suggesting
that candidemia episodes can result in severe illness.
Mortality occurred in 150 (57.4%) episodes during the
admission. The 7-day, 14-day and 30-day in-hospital
mortality rates were 28.3%, 39.8%, and 49.8%. The
mortality rate was lowest in patients infected with C.
parapsilosis (23.5%) (p = 0.03). Among the 225 patients
who received treatment, the 30-day in-hospital mortality
rate was 41.4%, while all but two (94.4%) of the non-
treated episodes resulted in death.
Predictors of mortality
The characteristics of survivors and non-survivors at
30 days are depicted in Table 3. Based on the multivari-
able logistic regression model, high SAPS II score (Odds
ratio, OR 1.08; 95% confidence interval, CI 1.06–1.11)
and renal replacement therapy (OR 4.31; CI 2.24–8.28)
were the only factors associated with 30-day mortality.
Presence of drains was a protective factor (OR 0.45; CI
0.21–0.94). Mortality occurred rapidly in many of the
non-survivors, hence receipt/type of antifungal therapy
was not included in this model, since antifungal therapy
could not be initiated in this subset of patients. To
examine the impact of initial antifungal therapy on
30-day mortality, a separate analysis was performed for
candidemia episodes where treatment was administered.
Results were similar when non-treated episodes were ex-
cluded. High SAPS II score, renal replacement therapy
and drains placement were significant factors in the
multivariable regression model (Table 4). The choice
and timing of initial antifungal therapy was not associ-
ated with mortality.
Discussion
We report here a comprehensive epidemiological study
of candidemia conducted at a large tertiary regional re-
ferral centre, which included the clinical characteristics,
antifungal treatment, species distribution, antifungal sus-
ceptibilities and outcomes of candidemia. Our study
showed that the incidence density of candidemia in our
institution has remained fairly stable since 2008. This
concurs with the general trend of stability in incidence
reported in other developed countries, such as the
United States and Europe [2, 17]. A recent study com-
paring candidemias among sites in Asia indicated that
rates in Singapore (0.15 episodes per 1000 patient-days)
were comparable with most other Asian countries, with
the exception of Taiwan (0.37 per 1000 patient-days) and
India (1.24 per 1000 patient-days) [10]. On a more global
scale, our rates were lower than those in Italy (0.33 per
1000 patient-days) [18], and Brazil (0.37 per 1000
patient-days) [19]. It appears that the species distribution
in our institution is changing. Previous local studies re-
ported a predominance of C. tropicalis, a finding com-
monly observed in tropical regions [10, 20]. We
observed an increasing proportion of C. glabrata from
11% in 2008 to 31% in 2015, overtaking C. tropicalis as
the predominant species.
Table 2 Clinical characteristics of candidemia episodes (Continued)
Infection Characteristics & Outcomes
Median (range) time to positive
culture, days
12 (0–282) 11 (0–282) 14 (0–123) 14 (0–79) 37 (0–104) 0.37
Median (range) time to reporting
positive culture, days
2 (0–10) 3 (0–9) 1 (0–10) 2 (1–5) 2(1–3) <0.001
Median (range) time to species
identification, days
5 (2–22) 6 (2–12) 4 (2–12) 5 (2–9) 5 (3–7) <0.001
Median (range) SAPS II score 49 (14–103) 48 (18–95) 55 (18–93) 48 (23–103) 44 (14–72) 0.01
Median (range) Pitts'
bacteraemia score
3 (0–14) 2 (0–11) 3 (0–12) 3 (0–11) 2 (0–8) 0.86
Severe sepsis at time of culture 151 (57.9) 49 (65.3) 43 (60.6) 33 (55.9) 13 (58.0) 0.08
ICU stay 131 (50.2) 36 (48.0) 35 (49.3) 30 (50.8) 16 (48.5) 0.99
Concurrent infection 127 (48.7) 33 (44.0) 36 (57.0) 30 (50.8) 16 (48.5) 0.83
Candida colonization/infection
at other sites
118 (45.2) 41 (54.7) 39 (54.9) 34 (57.6) 18 (54.5) 0.99
30-day in-hospital all-cause
mortality
130 (49.8) 38 (50.7) 42 (59.2) 28 (47.5) 9 (27.3) 0.03
All variables are denoted as number of patients with the characteristic or belonging to the category [n (%)], unless otherwise stated
Sub-group analyses are shown only for episodes involving major Candida spp. and not for mixed candidemia and less common species
Comorbidities < 10% in occurrence are not reflected
Significant variables are reflected in bold and italics
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Table 3 Characteristics of survivors vs. non-survivors
Survivors Non-survivors p
n = 134 n = 127
Demographics
Male sex 73 (54.5) 65 (51.2) 0.59
Median age (range) 64 (22–95) 65 (24–101) 0.81
Ward type <0.001a
Medical ward 66 (49.3) 44 (34.6)
Surgical ward 37 (27.6) 14 (11.0)
ICU 31 (23.1) 69 (54.3)
Elective admission 14 (10.4) 13 (10.2) 0.96
Comorbidities
Malignancies 58 (43.3) 48 (51.6) 0.37
Diabetes 53 (39.6) 50 (39.4) 0.97
Chronic renal failure 22 (16.4) 45 (35.4) <0.001
Hepatobiliary disorders 25 (18.7) 33 (26.0) 0.16
Myocardial infarction 19 (14.2) 24 (18.9) 0.30
Cerebrovascular disease 11 (8.2) 18 (14.2) 0.13
Median (range) Charlson score 4 (0–15) 5 (0–14) 0.09a
Median (range) SAPS II score 43 (14–82) 58 (27–103) <0.001a
Risk factors
Central venous catheter 89 (66.4) 103 (81.1) 0.007a
Drain 37 (27.6) 23 (18.1) 0.07a
Mechanical ventilation 47 (35.1) 64 (50.4) 0.01a
Total parenteral nutrition 28 (20.9) 24 (18.9) 0.69
Surgery 81 (60.4) 89 (70.1) 0.10
Gastrointestinal surgery 20 (14.9) 21 (16.5) 0.72
Renal replacement therapy 23 (17.2) 62 (48.8) <0.001a
Antimicrobial therapy 116 (86.6) 120 (94.5) 0.30
Antifungal therapy 27 (20.1) 24 (18.9) 0.79
Immunosuppressive therapy 33 (24.6) 43 (33.9) 0.10
Neutropenia 10 (7.5) 11 (8.7) 0.72
Therapy
Initial therapy <0.001b
Echinocandin 89 (66.4) 76 (59.8)
Azole 40 (29.9) 12 (9.4)
Others (Amphotericin or combination) 3 (2.2) 5 (3.9)
None 2 (1.5) 34 (26.8)
Received initial therapy within 24 h 58 (43.2) 64 (50.4) <0.001b
Infection Characteristics
Species 0.04a
C. albicans 32 (23.9) 27 (21.3)
C. glabrata 39 (29.1) 36 (28.3)
C. tropicalis 29 (21.6) 42 (33.1
C. parapsilosis 24 (17.9) 9 (7.1)
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With respect to antifungal susceptibilities, while C.
albicans and C. parapsilosis remained mostly suscep-
tible, fluconazole resistant rates of C. tropicalis was 17%.
Notably, the fluconazole MIC90 of C. tropicalis increased
from 2 μg/mL in 2007 to 64 μg/mL reported in our
study [20]. This MIC uptrend suggests that C. tropicalis,
one of the predominant species in our context, is in-
creasingly becoming less susceptible. Further molecular
investigations are underway to understand the mecha-
nisms related to azole resistance in these isolates.
Another noteworthy finding of our study was the
emergence of echinocandin resistance in the Southeast
Asia region. In the post-echinocandin era, there have
been increasing reports of echinocandin treatment fail-
ures in most clinically-relevant species, especially in C.
glabrata [7, 21–24]. Fortunately, resistance rates
remained rare in the local context. There were only
three (1.1%) isolates which were echinocandin-resistant,
of which two had fks mutations. To the best of our
knowledge, this is the first incidence of fks mutations in
Candida bloodstream isolates other than C. glabrata
identified locally. While the fks mutations identified in
our isolates have been previously described, it is interest-
ing to note that resistance developed rapidly (within
4 days of exposure to caspofungin) in one of the
patients. Development in resistance has been primarily
related to prolonged use of echinocandins, which was
observed in the other patient, who had received 30 days
of caspofungin prior to Candida isolation [22].
Our study observed a high 30-day mortality rate of
49%. Like many previous studies, we found that mortal-
ity was associated with severity of illness at onset of
candidemia, suggesting that the poor outcomes of
patients with candidemia is likely related to the poor
prognosis of these patients with multiple comorbidities
[25]. Receipt of renal replacement therapy was also asso-
ciated with 30-day mortality. This could be an indication
of the underlying organ dysfunction contributing to se-
verity of illness. Drains placement prior to Candida iso-
lation was found to be protective, suggesting that
perhaps source control could contribute to better sur-
vival in patients with secondary candidemia.
Initial antifungal choice did not appear to be associated
with mortality in our study. Although the Infectious Dis-
eases Society of America guidelines have recommended
the use of an echinocandin as a first-line agent, rando-
mised controlled trials conducted so far have yet to
conclusively demonstrate superiority of one agent over
another [26–28]. A recent study has also illustrated that
clinical severity, rather than initial antifungal strategy, was
significantly correlated with mortality [25]. One reason
why we were unable to detect any association of initial an-
tifungal choice with mortality could be because we did not
account for the appropriateness of the therapy in terms of
dosing. Furthermore, pharmacokinetic variability can re-
sult in fluctuating antifungal levels in individual patients
[29]. Perhaps, the impact of initial antifungal choice on
treatment outcomes can be better elucidated if antifungal
dosing was individualised, such as through the use of
therapeutic drug monitoring. This therapeutic approach is
currently being explored in our institution.
Although a large number of our patients received anti-
fungals in a timely fashion, there was still a delay in ther-
apy for some patients, with some receiving antifungals
more than a week after cultures were taken. The time to
administration of antifungals could be limited by the lack
of rapid diagnostic tests available in our institution. It
takes an average of two days to report a positive Candida
blood culture, and in some instances even up to a week.
Our study was not without limitations. This was a
single-centre study and our results might not be extrapo-
lated to other institutions as the epidemiology of
Table 4 Multivariable logistic regression model for mortality in
treated cases (n = 225)
Variable OR (95% CI)
SAPS II score 1.08 (1.05–1.11)
Presence of drains 0.44 (0.19–0.99)
Renal replacement therapy 5.54 (2.80–10.97)
Table 3 Characteristics of survivors vs. non-survivors (Continued)
Median (range) time to reporting positive culture, days 2 (0–10) 2 (0–10) 0.08a
Median (range) time to species identification, days 5 (2–16) 5 (2–22) 0.001a
Median (range) Candida score 2 (0–5) 3 (0–5) 0.01
Median (range) Pitts' bacteraemia score 2 (0–11) 5 (0–14) <0.001a
Severe sepsis at time of culture 64 (47.8) 87 (68.5) 0.001a
Concurrent bacterial infection 59 (46.5) 68 (53.5) 0.12
Candida colonization/infection at other sites 61 (45.5) 57 (44.9) 0.92
All variables are denoted as number of patients with the characteristic or belong to the category n (%), unless otherwise stated
Significant variables are reflected in bold and italics
aFactors entered into multivariable logistic regression model
bAdditional factors entered into multivariable logistic regression model including only treated episodes
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candidemia can be highly institution-specific. The retro-
spective nature of the study also precluded the analysis of
impact of time of catheter removal on mortality. Never-
theless, this study provides important epidemiological
findings which are instrumental in designing strategies for
better management of candidemia in our institution.
Conclusions
While incidence of candidemia appeared to be stable, inci-
dence of C. glabrata is increasing. C. glabrata and C.
tropicalis contributed to majority of the candidemia cases
in our institution. Decreasing azole susceptibilities to C.
tropicalis and the emergence of echinocandin resistance
suggests that susceptibility patterns may no longer be suf-
ficiently predicted by speciation in our institution. Routine
antifungal susceptibility, particularly for C. tropicalis,
might be essential to guide clinician to effectively manage
patients with invasive Candida infections. Candidemia
was associated with high mortality, and antifungal stew-
ardship efforts in individualising antifungal dosing
through therapeutic drug monitoring should be further
explored to improve outcomes in this population.
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